The impact of maternal-fetal omalizumab transfer on peanut-specific responses in an ex vivo placental perfusion model

Akash Kothari; Birgit Hirschmugl; Jean-Soo Lee; Birgit Pfaller; Klara Schmidthaler; Zsolt Szépfalusi; Christian Wadsack; Thomas Eiwegger

doi:10.1111/all.15468

The impact of maternal-fetal omalizumab transfer on peanut-specific responses in an ex vivo placental perfusion model

Akash Kothari, Birgit Hirschmugl, Jean-Soo Lee, Birgit Pfaller, Klara Schmidthaler, Zsolt Szépfalusi, Christian Wadsack, Thomas Eiwegger

Publikation: Beitrag in Fachzeitschrift (peer-reviewed) › Brief/kurzer Abriss

2 Zitate (Scopus)

Originalsprache	Englisch
Seiten (von - bis)	3684-3686
Seitenumfang	3
Fachzeitschrift	Allergy: European Journal of Allergy and Clinical Immunology
Jahrgang	77
Ausgabenummer	12
Frühes Online-Datum	4 Aug. 2022
DOIs	https://doi.org/10.1111/all.15468
Publikationsstatus	Veröffentlicht - Dez. 2022

Zugriff auf Dokument

10.1111/all.15468

Andere Dateien und Links

Verknüpfung zur Publikation in Scopus

Dieses zitieren

@article{b8b5d53370b8454c9dde776fcaffe2c8,

title = "The impact of maternal-fetal omalizumab transfer on peanut-specific responses in an ex vivo placental perfusion model",

keywords = "Arachis, Female, Humans, Maternal-Fetal Exchange, Omalizumab/therapeutic use, Peanut Hypersensitivity, Perfusion, Placenta, Pregnancy",

author = "Akash Kothari and Birgit Hirschmugl and Jean-Soo Lee and Birgit Pfaller and Klara Schmidthaler and Zsolt Sz{\'e}pfalusi and Christian Wadsack and Thomas Eiwegger",

note = "Funding Information: This work was supported by The Hospital for Sick Children (Food Allergy and Anaphylaxis Program, start‐up funds by the SickKids Research Institute and the Department of Pediatrics, Restracomp Graduate Scholarship to AK), and an Ontario Graduate Scholarship from the Province of Ontario to AK. Funding Information: AK, BH, JSL, BP, KS, and CW have nothing to disclose. ZS holds advisory board roles for Nutricia/Danone, Aimmune, and Sanofi. TE reports to act as local PI for company‐sponsored trials by DBV and sub‐investigator for Regeneron, holds grants from Innovation Fund Denmark, CIHR outside the submitted work. He is Co‐Investigator or scientific lead in three investigator‐initiated oral immunotherapy trials supported by the Food Allergy and Anaphylaxis Program SickKids and serves as an associate editor for Allergy. He/his laboratory received unconditional/in‐kind contributions from Macro Array Diagnostics and an unrestricted grant from ALK. He holds advisory board roles for ALK, Nutricia/Danone, and Aimmune.",

year = "2022",

month = dec,

doi = "10.1111/all.15468",

language = "English",

volume = "77",

pages = "3684--3686",

journal = "Allergy: European Journal of Allergy and Clinical Immunology",

issn = "0105-4538",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "12",

}

TY - JOUR

T1 - The impact of maternal-fetal omalizumab transfer on peanut-specific responses in an ex vivo placental perfusion model

AU - Kothari, Akash

AU - Hirschmugl, Birgit

AU - Lee, Jean-Soo

AU - Pfaller, Birgit

AU - Schmidthaler, Klara

AU - Szépfalusi, Zsolt

AU - Wadsack, Christian

AU - Eiwegger, Thomas

N1 - Funding Information: This work was supported by The Hospital for Sick Children (Food Allergy and Anaphylaxis Program, start‐up funds by the SickKids Research Institute and the Department of Pediatrics, Restracomp Graduate Scholarship to AK), and an Ontario Graduate Scholarship from the Province of Ontario to AK. Funding Information: AK, BH, JSL, BP, KS, and CW have nothing to disclose. ZS holds advisory board roles for Nutricia/Danone, Aimmune, and Sanofi. TE reports to act as local PI for company‐sponsored trials by DBV and sub‐investigator for Regeneron, holds grants from Innovation Fund Denmark, CIHR outside the submitted work. He is Co‐Investigator or scientific lead in three investigator‐initiated oral immunotherapy trials supported by the Food Allergy and Anaphylaxis Program SickKids and serves as an associate editor for Allergy. He/his laboratory received unconditional/in‐kind contributions from Macro Array Diagnostics and an unrestricted grant from ALK. He holds advisory board roles for ALK, Nutricia/Danone, and Aimmune.

PY - 2022/12

Y1 - 2022/12

KW - Arachis

KW - Female

KW - Humans

KW - Maternal-Fetal Exchange

KW - Omalizumab/therapeutic use

KW - Peanut Hypersensitivity

KW - Perfusion

KW - Placenta

KW - Pregnancy

UR - http://www.scopus.com/inward/record.url?scp=85135810448&partnerID=8YFLogxK

U2 - 10.1111/all.15468

DO - 10.1111/all.15468

M3 - Letter/short communication

C2 - 35924691

SN - 0105-4538

VL - 77

SP - 3684

EP - 3686

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

IS - 12

ER -